
The interview highlights the evolution of atopic dermatitis treatment, emphasizing options beyond topical steroids.

The interview highlights the evolution of atopic dermatitis treatment, emphasizing options beyond topical steroids.

In this segment of his Fall Clinical interview, Nestor discussed actinic keratosis and shifts in the rates of skin cancer.

This conference preview with Viet Le, DMSc, PA-C, for the 2025 AHA Scientific Sessions highlights the top 5 trials to watch.

Mayo explains findings from a pooled analysis of pruritus data from RESPONSE and ENHANCE highlighting seladelpar’s impact on itch in PBC.

Nestor spoke in this interview about avoiding cosmetic complications and educating patients on available treatments like toxins and fillers.

In this interview, Swanson highlights the topics covered in her session on oral and injectable medications, and specifically icotrokinra, in the psoriasis pipeline.

Keefer emphasizes the importance of treatment satisfaction and health-related quality of life in IBD and reviews findings from ASPIRE-CD.

Redd reviews real-world data highlighting low rates of biopsies performed among patients with esophageal food impaction-related emergency department visits.

Dellon reviews data from a post-hoc analysis of dysphagia and odynophagia in LIBERTY EoE TREET and a pooled analysis of endoscopic improvement in 2 trials.

Njei explains the utility of Fibro-GPT for detecting advanced fibrosis and predicting hepatic decompensation in MASLD.

This Fall Clinical interview features a series of highlights from Culton’s portion of the session ‘Bullous Pemphigoid: The Time to Treat is Now.’

In this episode, Michelle Rodrigues, MBBS, joins Skin of Color Savvy from EADV 2025 to discuss facial hyperpigmentation in richly pigmented skin.

Ahmad reviews findings from the OCULUS trial highlighting the benefits of holding a single dose of GLP-1 and GIP-1 agonists prior to upper endoscopy.

Markley describes the importance of monitoring bone health in patients with IBD and celiac disease and explains her research showing low screening rates.

Physicians experience significant challenges with increasing administrative burdens impacting patient care. Study shows AI scribes can help reduce burnout.

In this interview at Fall Clinical, Song highlights takeaways from his portion of the session ‘30 Tips in 30 Minutes.’

Song interviewed with the team regarding his session, discussing recent data on IL-23 inhibition in patients with psoriasis.

Alexis spoke in this segment of his Fall Clinical interview on takeaways from his presentation titled ‘Melasma and Other Hyperpigmentation Disorders.’

In this Fall Clinical interview, Alexis highlights several tips for clinicians covered in his session at the conference titled ‘30 Tips in 30 Minutes.’

This interview with Prince Adotama, MD, at Fall Clinical highlights several takeaways from his session on treating bullous pemphigoid.

In this segment of her Fall Clinical interview, Shahriari highlights a session IL-13 inhibition and management of atopic dermatitis.

This interview at Fall Clinical highlights a session on clinical pearls related to diagnosing prurigo nodularis in patients with skin of color.


This interview highlights the takeaways from Nestor’s Fall Clinical session titled ‘What Did 2025 Bring to the Table in Dermatology?’

Saxena discusses lorundrostat’s efficacy in lowering systolic blood pressure regardless of additional antihypertensive medications.

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Mucus plugs are an increasingly present issue in uncontrolled asthma. Lugogo discusses promising findings from VESTIGE that addresses them.

Maher discussed taladegib's potential to improve FVC, rather than slow decline, in people with idiopathic pulmonary fibrosis.

Kolaitis discussed interim findings from the ASCENT trial, which showed ability to increase treprostinil dosing while maintaining a safe and efficacious profile.

Castro discusses new data from CHEST 2025 showing the value of baseline blood eosinophils and FeNO in understanding potential dupilumab outcomes.